Accepted Manuscript



Missense variant in *TREML2* protects against Alzheimer's Disease

Bruno A. Benitez, Sheng Chih Jin, Rita Guerreiro, Rob Graham, Jenny Lord, Denise Harold, Rebecca Sims, Jean-Charles Lambert, J. Raphael Gibbs, Jose Bras, Celeste Sassi, Oscar Harari, Sarah Bertelsen, Michelle K. Lupton, John Powell, Celine Bellenguez, Kristelle Brown, Christopher Medway, Patrick CG. Haddick, Marcel P. van der Brug, Tushar Bhangale, Ward Ortmann, Tim Behrens, Richard Mayeux, Margaret A. Pericak-Vance, Lindsay A. Farrer, Gerard D. Schellenberg, Jonathan L. Haines, Jim Turton, Anne Braae, Imelda Barber, Anne M. Fagan, David M. Holtzman, John C. Morris, Julie Williams, John Kauwe, Philippe Amouyel, Kevin Morgan, Andy Singleton, John Hardy, Alison M. Goate, Carlos Cruchaga

PII: S0197-4580(13)00649-0

DOI: 10.1016/j.neurobiolaging.2013.12.010

Reference: NBA 8704

To appear in: *Neurobiology of Aging*

Received Date: 29 August 2013

Revised Date: 9 December 2013

Accepted Date: 13 December 2013

Please cite this article as: Benitez, B.A, Jin, S.C., Guerreiro, R., Graham, R., Lord, J., Harold, D., Sims, R., Lambert, J.-C., Gibbs, J.R., Bras, J., Sassi, C., Harari, O., Bertelsen, S., Lupton, M.K., Powell, J., Bellenguez, C., Brown, K., Medway, C., Haddick, P.C., van der Brug, M.P, Bhangale, T., Ortmann, W., Behrens, T., Mayeux, R., Pericak-Vance, M.A., Farrer, L.A., Schellenberg, G.D., Haines, J.L., Turton, J., Braae, A., Barber, I., Fagan, A.M., Holtzman, D.M., Morris, J.C., , , Williams, J., Kauwe, J., Amouyel, P., Morgan, K., Singleton, A., Hardy, J., Goate, A.M., Cruchaga, C., Missense variant in *TREML2* protects against Alzheimer's Disease, *Neurobiology of Aging* (2014), doi: 10.1016/j.neurobiolaging.2013.12.010.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Missense variant in *TREML2* protects against Alzheimer's Disease

Authors and Affiliations

Bruno A Benitez[1*], Sheng Chih Jin[1*], Rita Guerreiro[12,13], Rob Graham[9], Jenny Lord[20], Denise Harold[8], Rebecca Sims[8], Jean-Charles Lambert[22,23,24], J. Raphael Gibbs[12,13], Jose Bras[12], Celeste Sassi[12,13], Oscar Harari[1], Sarah Bertelsen[1], Michelle K. Lupton[21], John Powell[21], Celine Bellenguez[22,23,24], Kristelle Brown[20], Christopher Medway[20], Patrick CG Haddick[9], Marcel P van der Brug[9], Tushar Bhangale[10], Ward Ortmann[11], Tim Behrens[11], Richard Mayeux[15], Margaret A. Pericak-Vance[16], Lindsay A. Farrer[17], Gerard D. Schellenberg[18], Jonathan L. Haines[19], Jim Turton[20], Anne Braae[20], Imelda Barber[20], Anne M. Fagan[2,6,7], David M. Holtzman[2,5,6,7], John C. Morris[2,3,6,7], The 3C Study Group, the EADI consortium, the Alzheimer Disease Genetic Consortium (ADGC), Alzheimer's Disease Neuroimaging Initiative (ADNI), the GERAD Consortium[†], Julie Williams[8], John Kauwe[14], Philippe Amouyel[22,23,24], Kevin Morgan[20], Andy Singleton[11], John Hardy[11], Alison M. Goate,[1,2,4,6,7,25] and Carlos Cruchaga[1,7,25]

Departments of [1]Psychiatry, [2]Neurology, [3]Pathology and Immunology, [4]Genetics, [5]Developmental Biology, [6]Knight Alzheimer's Disease Research Center, and [7]Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110,

[8]Institute of Psychological Medicine and Clinical Neurosciences, Cardiff University, UK

[9]Diagnostic Discovery Department, Genentech Inc., South San Francisco, CA 94080, USA

[10]Department of Bioinformatics and Computational Biology, Genentech Inc., South San Francisco, CA 94080, USA Genentech, South San Francisco, CA 94080, USA

[11]Human Genetics Department, Genentech Inc., South San Francisco, CA 94080, USA

[12]Department of Molecular Neuroscience, UCL Institute of Neurology, London WC1N 3BG, UK.

[13]Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, United States of America

[14]Department of Biology, Brigham Young University, Provo, UT, 84602.

[15]Department of Neurology, Taub Institute on Alzheimer's Disease and the Aging Brain, and Gertrude H. Sergievsky Center, Columbia University, New York, New York, USA.

[16]The John P. Hussman Institute for Human Genomics, and Dr. John T. Macdonald Foundation Department of Human Genetics, University of Miami, Miami, Florida, USA

[17] Departments of Medicine (Biomedical Genetics, Neurology, Ophthalmology, Epidemiology, and Biostatistics, Boston University Schools of Medicine and Public Health, Boston, Massachusetts, USA

[18]Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA

[19]Department of Molecular Physiology and Biophysics, Vanderbilt Center for Human Genetics Research, Vanderbilt University, Nashville, Tennessee, USA.

[20]Human Genetics, School of Molecular Medical Sciences, University of Nottingham, Nottingham, NG7 2UH, UK.

[21]Institute of Psychiatry, King's College London, London, UK

[22]Inserm, U744, Lille, 59000, France. [23]Universite Lille 2, Lille, 59000, France. [24]Institut Pasteur de Lille, Lille, 59000, France

[25]To whom correspondence should be addressed at: Department of Psychiatry, Washington University School of Medicine, 660 South Euclid Avenue B8134, St. Louis, MO 63110. E-mail: goatea@psychiatry.wustl.edu, tel. 314-362-8691, fax. 314-747-2983, or E-mail: cruchagac@psychiatry.wustl.edu, tel. 314-286-0546, fax. 314-747-2983

*Joint First Authors who contributed equally

†Data used in the preparation of this article were obtained from the Genetic and Environmental Risk for Alzheimer's disease (GERAD1) Consortium. As such, the investigators within the GERAD1 consortia contributed to the design and implementation of GERAD1 and/or provided data but did not participate in analysis or writing of this report. A full list of GERAD1 investigators shall be included in either supplementary content or acknowledgements.

ACCEPTED MANUSCRIPT

ACCEPTED MANUSCRIPT

Abstract

TREM and TREM-like receptors are a structurally similar protein family encoded by genes clustered on chromosome 6p21.11. Recent studies have identified a rare coding variant (p.R47H) in *TREM2* that confers a high risk for Alzheimer's disease (AD). In addition, common SNPs in this genomic region are associated with cerebrospinal fluid (CSF) biomarkers for AD and a common intergenic variant found near the *TREML2* gene has been identified to be protective for AD. However, little is known about the functional variant underlying the latter association or its relationship with the p.R47H. Here, we report comprehensive analyses using whole-exome sequencing data, CSF biomarker analyses, meta-analyses (16,254 cases and 20,052 controls) and cell-based functional studies to support the role of the *TREML2* coding missense variant p.S144G (rs3747742) as a potential driver of the meta-analysis AD-associated GWAS signal. Additionally, we demonstrate that the protective role of *TREML2* in AD is independent of the role of *TREM2* gene as a risk factor for AD.

ACCEPTED MANUSCRIPT

1. Introduction

Genome-wide association studies (GWAS) are a very powerful approach for identification of novel loci associated with disease status or other complex traits. However, these single nucleotide polymorphisms (SNPs) are usually not the functional variants driving the association and, in many cases, regional linkage disequilibrium (LD) prevents identification of a single candidate gene in the region. Often, additional studies are required to demonstrate unambiguously that the gene/variant implicated in disease risk is functionally related to pathogenesis.

Recently, the International Genomics of Alzheimer's Project (IGAP) identified 11 new loci ($P<10^{-8}$) associated with risk for Alzheimer's Disease (AD), and 13 additional suggestive loci (p value between10^{-6} and 10^{-8}) (Lambert, et al., 2013). Among the latter group, there is an inter-genic SNP (rs9381040 ($P<6.3\times10^{-7}$)) located 5.5 Kb downstream from *TREML2* and 24 Kb upstream from *TREM2*. The TREM and TREM-like receptor genes clustered on chromosome 6p21.1 (Ford and McVicar, 2009) have different patterns of LD among them (Cruchaga, et al., 2013). This genomic region has previously been implicated in genetic risk for AD (Jonsson, et al., 2012,Benitez, et al., 2013,Bertram, et al., 2013,Cruchaga, et al., 2013,Guerreiro, et al., 2013,Reitz and Mayeux, 2013). A low frequency missense variant in *TREM2* (p.R47H, minor allele frequency=0.003) was reported to substantially increase risk for AD (Benitez, et al., 2013,Guerreiro, et al., 2013). SNPs in this region were also found to be associated with a cerebrospinal fluid (CSF) biomarker for AD (phospho-tau_{181} levels) (Cruchaga, et al., 2013). Due to the design of the IGAP study (a meta-analysis) and the low frequency of the *TREM2* variant, it was not possible to determine whether the GWAS signal of this variant (rs9381040) was independent of the *TREM2*-p.R47H variant. In this study, we used exome sequencing data to identify the most likely functional variant in *TREML2* responsible for the GWAS signal and to determine whether this signal is independent of *TREM2*-p.R47H (rs75932628) variant.

ACCEPTED MANUSCRIPT

2. Methods

2.1. Exome sequencing Knight-ADRC

Enrichment of coding exons and flanking intronic regions was performed using a solution hybrid selection method with the SureSelect® human all exon 50Mb kit (Agilent Technologies, Santa Clara, California) following the manufacturer's standard protocol on 46 unrelated AD cases and 39 unrelated controls from the Knight-ADRC. This was performed by the Genome Technology Access Center at Washington University in St Louis (https://gtac.wustl.edu/). The captured DNA was sequenced by paired-end reads on the HiSeq 2000 sequencer (Illumina, San Diego, California). Raw sequence reads were aligned to the reference genome NCBI 36/hg18 by using Novoalign (Novocraft Technologies, Selangor, Malaysia). Base/SNP calling was performed using SNP Sam tools(Li, et al., 2009). SNP annotation was carried out using version 5.07 of SeattleSeq Annotation server (see URL)(Benitez, et al., 2011). On average, 95% of the exome had a fold coverage higher than eight.

2.2. UK-NIA dataset

A description of the UK-NIA dataset can be found in Guerreiro et al., 2013 (Guerreiro, et al., 2013). Briefly, this dataset includes whole-exome sequencing data from 143 AD cases and 183 controls (Table 1).

2.3. ADGC material and methods

Data used in the preparation of this article were obtained from the ADGC. A description of the samples included in the study as well as the methods used can be found at Naj et al., 2011(Naj, et al., 2011). Imputed data from 10,067 AD cases and 9,606 controls from the ADGC were used in this study (Naj, et al., 2011). Genome-wide imputation was performed per cohort using MACH software with HapMap phase 2 (release 22) CEPH Utah pedigrees (CEU) reference haplotypes and genotype data passing quality control as inference. Imputation quality was determined as R^2 and only SNPs imputed with $R^2 \geq 0.50$ were included in the analysis. A multivariate logistic

ACCEPTED MANUSCRIPT

regression was performed to evaluate the association between genetic markers and risk for LOAD adjusting for age, gender, population substructure, and study-specific effects.

2.4. For use of GERAD1 genotype data from 'the 610 group':

Data used in the preparation of this article were obtained from the Genetic and Environmental Risk for Alzheimer's disease (GERAD) Consortium. The imputed GERAD sample comprised 3,177 AD cases and 974 healthy elderly (age >70) controls with available age and gender data. Cases and elderly screened controls were recruited by the Medical Research Council (MRC) Genetic Resource for AD (Cardiff University; Institute of Psychiatry, London; Cambridge University; Trinity College Dublin), the Alzheimer's Research UK (ARUK) Collaboration (University of Nottingham; University of Manchester; University of Southampton; University of Bristol; Queen's University Belfast; the Oxford Project to Investigate Memory and Ageing (OPTIMA), Oxford University); Washington University, St Louis, United States; MRC PRION Unit, University College London; London and the South East Region AD project (LASER-AD), University College London; Competence Network of Dementia (CND) and Department of Psychiatry, University of Bonn, Germany; the National Institute of Mental Health (NIMH)AD Genetics Initiative. 6,129 population controls were drawn from large existing cohorts with available GWAS data, including the 1958 British Birth Cohort (1958BC) (http://www.b58cgene.sgul.ac.uk), the KORA F4 Study and the Heinz Nixdorf Recall Study. All AD cases met criteria for either probable (NINCDS-ADRDA, DSM-IV) or definite (CERAD) AD. All elderly controls were screened for dementia using the MMSE or ADAS-cog, were determined to be free from dementia at neuropathological examination or had a Braak score of 2.5 or lower. Genotypes from all cases and controls were previously included in the AD GWAS by Harold and colleagues (2009). Imputation of the dataset was performed using IMPUTE2 and the 1000 genomes (http://www.1000genomes.org/) Dec2010 reference panel (NCBI build 37.1). The imputed data was then analyzed using logistic regression including covariates for country of origin, gender, age and 3 principal components obtained with EIGENSTRAT (Patterson, et al.,

ACCEPTED MANUSCRIPT

2006) software based on individual genotypes for the GERAD study participants.

2.5. European Alzheimer's disease initiative (EADI) consortium

All AD cases were ascertained by neurologists from Bordeaux, Dijon, Lille, Montpellier, Paris, Rouen, and were identified as French Caucasian (Group, 2003,Dreses-Werringloer, et al., 2008). Clinical diagnosis of probable AD was established according to the DSM-III-R and NINCDS-ADRDA criteria. Controls were selected from the 3C Study(Group, 2003). This cohort is a population-based, prospective (7-years follow-up) study of the relationship between vascular factors and dementia. It has been carried out in three French cities: Bordeaux (southwest France), Montpellier (southeast France) and Dijon (central eastern France). A sample of non-institutionalized, over-65 subjects was randomly selected from the electoral rolls of each city. Between January 1999 and March 2001, 9,686 subjects meeting the inclusion criteria agreed to participate. Following recruitment, 392 subjects withdrew from the study. Thus, 9,294 subjects were finally included in the study (2,104 in Bordeaux, 4,931 in Dijon and 2,259 in Montpellier). Genomic DNA samples 38 of 7,200 individuals were transferred to the French Centre National de Génotypage (CNG). First stage samples that passed DNA quality control were genotyped with Illumina Human 610-Quad BeadChips (n=452). At the end, we removed 308 samples because they were found to be first- or second-degree relatives of other study participants, or were assessed non-European descent based on genetic analysis using methods described in(Heath, et al., 2008). In this final sample, at 7 years of follow-up, 459 individuals suffered from AD with 97 prevalent and 362 incident cases. These AD cases were included as cases in the EADI discovery dataset. We retained the other individuals as controls (n=6,017). The imputation was performed using 1000 Genomes multi-ethnic data (1000G Phase 1 integrated variant set release v3) as reference panel. Imputation was performed in two steps: pre-phasing with SHAPEIT (v2), followed by imputation with IMPUTE2. SNPs are used in the imputation process if call rate > 98%, HWE p value > 1e-6, MAF> 1.

2.6. Cerebrospinal fluid levels (CSF) dataset

A description of the CSF dataset used in this study can be found in Cruchaga et al (Cruchaga, et al., 2013) and data included 1,269 unrelated individuals recruited through the Knight-ADRC at Washington University (n=501, 73% CDR=0), the Alzheimer's Disease Neuroimaging Initiative (n=394, 27% CDR=0), a biomarker Consortium of Alzheimer Disease Centers coordinated by University of Washington (UW) (n=323, 61% CDR=0), and the University of Pennsylvania (UPenn) (n=51, 2% CDR=0). Briefly, CSF tau, ptau and $A\beta_{42}$ levels were from research participants enrolled in longitudinal studies at the Knight-ADRC, ADNI, UW and UPenn. CSF collection and $A\beta_{42}$, tau and ptau181 measurements were performed as described previously (Fagan, et al., 2006). The samples were genotyped using Illumina chips. Cases received a diagnosis of dementia of the Alzheimer's type (DAT), using criteria equivalent to the National Institute of Neurological and Communication Disorders and Stroke-Alzheimer's Disease and Related Disorders Association for probable A (McKhann, et al., 1984). Controls received the same assessment as the cases but were non-demented. All individuals were of European descent and written consent was obtained from all participants.

2.7. Statistical Analyses

We performed multivariate logistic regression to evaluate the association between genetic markers and risk for LOAD adjusting for age, gender, population substructure, and study specific effects using PLINK (http://pngu.mgh.harvard.edu/purcell/plink/). Conditional analysis was performed to identify additional independent signals by conditioning on the top case-control GWAS hits. We first estimated the odds ratios for SNPs across cohorts. These models calculate crude odds ratios and confidence intervals from counts of heterozygous in case patients and controls in each study. Then we performed a fixed-effect model to combine the odds ratios from study-specific estimates into a summary measure. No multiple-testing correction was used in

our analyses. The heterogeneity of effects were evaluated using Woolf's test for heterogeneity (Woolf, 1955). Meta-analysis was conducted using the META package (http://www.stats.ox.ac.uk/~jsliu/meta.html) in R (version 3.0.1).

Association of CSF ptau with the genetic variants was analyzed as described previously (Cruchaga, et al., 2010,Cruchaga, et al., 2011,Kauwe, et al., 2011). Briefly, CSF ptau values were log transformed to approximate a normal distribution. Because the CSF levels were measured using different platforms (Innotest plate ELISA vs AlzBia3 bead-based ELISA, respectively), we were not able to combine the raw data. We extracted from the log-transformed value, the mean within each series for the log-transformation. No significant differences in the transformed CSF values of the different series were found. We used SAS to analyze the association of SNPs with CSF biomarker levels. Age, gender, site, and first three principal components were included as covariates. We also performed conditional analyses by including several variants in the model.

2.8. Genotyping

Rs9381040 and rs3747742 were extracted from the GWAS data (Cruchaga, et al., 2013), and confirmed by direct genotyping. The *TREM2*-p.R47H was genotyped using KASP™ genotyping assay (LGC Genomics), as previously described (Cruchaga, et al., 2009,Cruchaga, et al., 2010,Cruchaga, et al., 2012,Benitez and Cruchaga, 2013) on 2,000 cases and controls from the Knight-ADRC.

2.9. Cell-based analysis

Primary astrocytes and microglia were prepared from 2 litters (16 pups) of P1 C57BL/6 mice. Individual mice were pooled and 12 replicate co-cultures were plated in 25cm^2 flasks. Co-cultures were treated with 0.2 ng/mL of mouse IL-1β (R&D 401-ML/CF) for 24 hours. Microglia was detached from the plate by shaking at 125 rpm for 1 hour in a 37C incubator. RNA was extracted using MiRNeasy mini kit (Qiagen 217004), according to manufacturer's instructions.

qPCR assays for mouse Trem2 (ID: Mm04209424), Treml2 (ID: Mm01277362) and Saa3 (ID: Mm00441203) were obtained from Life Technologies.

3. Results

Eight coding variants were validated in the *TREML2* gene (Table 1), which constitute the 53% (8/15) of the missense variants reported for *TREML2* gene in the Exome Variant server (release ESP6500SI-V2) for European Americans. Only three variants exhibit a MAF % higher than 1%: p.V25A (MAF=5%), p.T129S (MAF=4.5%) and p.S144G (MAF=30%). Interestingly, according to our exome sequencing results all these variants are more common in controls than in AD cases, however they did not reach statistical significance with our whole-exome sequence sample size, although the three of them are more common in controls than AD cases. (Table 1). Interestingly, the missense variant p.S144G (rs3747742) exhibited the highest LD (R^2 = 0.73, D' = 0.86) with the GWAS SNP, rs9381040 (Table 1) and the higher MAF among the validated missense variants in *TREML2,* which made it suitable for further analysis. Next, we performed a meta-analysis of the data from the ADGC, GERAD, EADI, and ARUK; studies (16,254 cases and 20,052 controls) we found that the minor alleles of both rs9381040 ($p=1.21\times10^{-5}$; OR=0.92, CI=0.88-0.95), and rs3747742 ($p=8.66\times10^{-5}$; OR=0.93, CI=0.89-0.96) reduce risk for AD (Figure 1, Panel A and B). When rs3747742 is included in a logistic regression model as a covariate, rs9381040 is no longer significant (p=0.43), and vice-versa, indicating that these SNPs are tagging the same signal. In addition, *TREM2*-p.R47H (rs75932628) is successfully imputed (imputation quality score info =0.84 and 0.79) in the GERAD and EADI studies, and it displays a strong association with AD risk ($p=1.3\times10^{-3}$; OR=1.92, CI=1.29-2.85) (Figure 1, Panel C). When rs3747742 or rs9381040 are included as covariates in a conditional analysis, rs75932628 remains highly significant ($p=1.27\times10^{-4}$ and $p=1.19\times10^{-4}$, respectively) (Figure 1, Panel D), suggesting that the *TREML2* and *TREM2* signals are independent from each other.

We also performed a linear regression analysis for rs9381040 and rs3747742 with CSF levels of tau and phospho-tau-181 (ptau) (n=1,269 individuals) (Cruchaga, et al., 2013). Rs9381040

($p=4.11\times10^{-4}$, Beta=-0.02) and rs3747742 (1.4×10^{-4}, Beta=-0.02) both exhibit a strong association with CSF ptau levels. The respective associations with CSF ptau are no longer significant when either SNP is included as a covariate in the conditional analysis. These results confirm via two independent datasets that the associations of rs9381040 and rs3747742 with CSF biomarker levels and with AD risk represent the same signal. The *TREM2*-p.R47H variant was also genotyped in a subset of the CSF samples (n=835). In these samples, three variants, rs9381040 (p=0.04, Beta=-0.02) (Figure 2, Panel A), rs3747742 (p=0.02, Beta=-0.02) (Figure 2, Panel B) and rs75932628 (p=0.0016, Beta=0.2) (Figure 2, Panel C) demonstrate a nominally significant association with CSF ptau levels. To determine whether the *TREML2* signal (rs3747742) is independent of *TREM2*-p.R47H, we removed all of the p.R47H carriers from the analysis. Rs3747742 remained significantly associated with CSF ptau levels (p=0.03) (Figure 2, Panel D). Furthermore, when *TREM2*-p.R47H was included in the model as a covariate for rs3747742 analysis, the association remained significant (p=0.02), which suggests that the *TREM2* and *TREML2* signals are independent. Importantly, these associations confirmed the direction of the effect on CSF ptau levels: the minor allele of rs3747742 is associated with lower ptau levels (Beta=-0.02) and is predicted to be protective for AD risk (OR=0.91; CI=0.86-0.97), while the minor allele of *TREM2*-p.R47H is associated with an increased risk for AD (OR=1.91, CI=1.85-1.97) and higher levels of CSF ptau (Beta=0.2).

In addition, TREM and TREM-like receptors modulate the innate immune response by either amplifying or dampening TLR-induced signals, playing critical roles in fine-tuning the inflammatory response (Ford and McVicar, 2009). TREM and TREM-like receptors demonstrate different patterns of expression and are likely to play different roles in the inflammatory response. To further understand the relative expression of *TREM2* and *TREML2,* we analyzed gene expression in primary mouse microglia and astrocytes stimulated by IL-1β. Treatment of microglia with IL-1β repressed expression of *TREM2* (Figure 3, Panel A), but increased expression of *TREML2* (Figure 3, Panel B). The opposing effects of this inflammatory cytokine

on *TREM2/TREML2* expression is consistent with our genetic data and with evidence that *TREM2/DAP12* antagonizes inflammatory signaling in microglia while *TREML2* is not coupled to *DAP12* signaling and plays a pro-inflammatory role (Ford and McVicar, 2009).

4. Discussion

In summary, these results demonstrate that the associations of missense variants in *TREM2* and *TREML2* with AD risk are independent. Moreover, our analyses suggest that the AD-associated GWAS signal is likely driven by the *TREML2* coding missense variant p.S144G (rs3747742); it results in a similar odds ratio to rs9381040. We also validated two other coding variants p.V25A and p.S129T in *TREML2* gene in moderate LD (r^2=0.05 and D'=1) with the GWAS SNP, which both exhibited a higher frequency among controls than in AD cases (Table 1). However, for both variants we only obtained data by whole-exome sequencing which limited our analysis about the role that these variants may play in the association of *TREML2* with AD risk. In order to prove that these additional variants are associated with AD risk we will need a larger sample size. Additionally, the purpose of this study was to find a functional coding variant in the *TREML2* gene that could explain the association for *TREML2* which was found in the recent IGAP meta-analysis. Our data suggest that there is a coding variant in *TREML2* that could explain the GWAS signal, but our data cannot rule-out of the presence of functional variants outside of the coding region.

We conclude that at least two genes in this gene cluster influence risk for AD: *TREM2*-p.R47H is associated with increased risk for AD (OR=1.91, CI=1.85-1.97) and *TREML2*-p.S144G is associated with reduced risk for AD (OR=0.91; CI=0.86-0.97). The mechanisms by which these variants influence AD risk are not currently understood, but it has been suggested that modulation of microglial activation might influence clearance of Aβ (Benitez, et al., 2011). These results underline the importance of the inflammatory response in modulating risk for AD and suggest that other genes in this gene family may also harbor risk alleles for AD.

ACCEPTED MANUSCRIPT

Acknowledgements

This work was supported by grants from NIH (P30-NS069329-01, R01-AG044546, R01-AG035083, R01-AG16208, P50-AG05681, P01-AG03991, P01-AG026276, AG05136 and PO1-AG05131, U01-AG032984, AG010124, R01-AG042611), the Alzheimer Association (NIRG-11-200110) and the Barnes-Jewish Hospital Foundation. This research was conducted while CC was a recipient of a New Investigator Award in Alzheimer's Disease from the American Federation for Aging Research. CC is a recipient of a BrightFocus Foundation Alzheimer's Disease Research Grant (A2013359S). The authors thank the Clinical and Genetics Cores of the Knight ADRC at Washington University for clinical and cognitive assessments of the participants and for *APOE* genotypes and the Biomarker Core of the Adult Children Study at Washington University for the CSF collection and ptau assays.

This study incorporated imputed summary results from the GERAD1 genome-wide association study. GERAD Acknowledgements: Cardiff University was supported by the Wellcome Trust, Medical Research Council (MRC), Alzheimer's Research UK (ARUK) and the Welsh Assembly Government. ARUK supported sample collections at the Kings College London, the South West Dementia Bank, Universities of Cambridge, Nottingham, Manchester and Belfast. The Belfast group acknowledges support from the Alzheimer's Society, Ulster Garden Villages, N.Ireland R&D Office and the Royal College of Physicians/Dunhill Medical Trust. The MRC and Mercer's Institute for Research on Ageing supported the Trinity College group. The South West Dementia Brain Bank acknowledges support from Bristol Research into Alzheimer's and Care of the Elderly. The Charles Wolfson Charitable Trust supported the OPTIMA group. Washington University was funded by NIH grants, Barnes Jewish Foundation and the Charles and Joanne Knight Alzheimer's Research Initiative. Patient recruitment for the MRC Prion Unit/UCL

Department of Neurodegenerative Disease collection was supported by the UCLH/UCL Biomedical Centre. LASER-AD was funded by Lundbeck SA. The Bonn group was supported by the German Federal Ministry of Education and Research (BMBF), Competence Network Dementia and Competence Network Degenerative Dementia, and by the Alfried Krupp von Bohlen und Halbach-Stiftung. The GERAD Consortium also used samples ascertained by the NIMH AD Genetics Initiative.

The KORA F4 studies were financed by Helmholtz Zentrum München; German Research Center for Environmental Health; BMBF; German National Genome Research Network and the Munich Center of Health Sciences. The Heinz Nixdorf Recall cohort was funded by the Heinz Nixdorf Foundation (Dr. jur. G.Schmidt, Chairman) and BMBF. Coriell Cell Repositories is supported by NINDS and the Intramural Research Program of the National Institute on Aging. We acknowledge use of genotype data from the 1958 Birth Cohort collection, funded by the MRC and the Wellcome Trust which was genotyped by the Wellcome Trust Case Control Consortium and the Type-1 Diabetes Genetics Consortium, sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Allergy and Infectious Diseases, National Human Genome Research Institute, National Institute of Child Health and Human Development and Juvenile Diabetes Research Foundation International.

We thank the Alzheimer's Research UK (ARUK) consortium for collection of the samples used, and the patients and families whose participation made this work possible. We also thank ARUK and the Big Lottery Fund for financial support of this work, and ARUK for funding the PhD studentship of Jenny Lord.

EADI1 was supported by the French National Fondation on Alzheimer's disease and related disorders. Data management involved the Centre National de Génotypage, the Institut Pasteur

ACCEPTED MANUSCRIPT

de Lille, Inserm, FRC (fondation pour la recherche sur le cerveau) and Rotary. This work has been developed and supported by the LABEX (laboratory of excellence program investment for the future) DISTALZ grant (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease). The Three-City Study was performed as part of collaboration between the Institut National de la Santé et de la Recherche Médicale (Inserm), the Victor Segalen Bordeaux II University and Sanofi-Synthélabo. The Fondation pour la Recherche Médicale funded the preparation and initiation of the study. The 3C Study was also funded by the Caisse Nationale Maladie des Travailleurs Salariés, Direction Générale de la Santé, MGEN, Institut de la Longévité, Agence Française de Sécurité Sanitaire des Produits de Santé, the Aquitaine and Bourgogne Regional Councils, Fondation de France and the joint French Ministry of Research/INSERM "Cohortes et collections de données biologiques" programme. Lille Génopôle received an unconditional grant from Eisai.

Disclosure statement for authors.

The authors report no conflicts of interest.

All participants had agreed by signed informed consent to participate in genetic studies approved by our Institutional Review Board.

ACCEPTED MANUSCRIPT

REFERENCES

Benitez, B.A., Alvarado, D., Cai, Y., Mayo, K., Chakraverty, S., Norton, J., Morris, J.C., Sands, M.S., Goate, A., Cruchaga, C. 2011. Exome-sequencing confirms DNAJC5 mutations as cause of adult neuronal ceroid-lipofuscinosis. PLoS One 6(11), e26741. doi:10.1371/journal.pone.0026741.

Benitez, B.A., Cooper, B., Pastor, P., Jin, S.C., Lorenzo, E., Cervantes, S., Cruchaga, C. 2013. TREM2 is associated with the risk of Alzheimer's disease in Spanish population. Neurobiol Aging 34(6), 1711 e15-7. doi:10.1016/j.neurobiolaging.2012.12.018.

Benitez, B.A., Cruchaga, C. 2013. TREM2 and neurodegenerative disease. N Engl J Med 369(16), 1567-8. doi:10.1056/NEJMc1306509#SA4.

Bertram, L., Parrado, A.R., Tanzi, R.E. 2013. TREM2 and neurodegenerative disease. N Engl J Med 369(16), 1565. doi:10.1056/NEJMc1306509#SA2.

Cruchaga, C., Fernandez-Seara, M.A., Seijo-Martinez, M., Samaranch, L., Lorenzo, E., Hinrichs, A., Irigoyen, J., Maestro, C., Prieto, E., Marti-Climent, J.M., Arbizu, J., Pastor, M.A., Pastor, P. 2009. Cortical atrophy and language network reorganization associated with a novel progranulin mutation. Cereb Cortex 19(8), 1751-60. doi:bhn202 [pii] 10.1093/cercor/bhn202.

Cruchaga, C., Kauwe, J.S., Harari, O., Jin, S.C., Cai, Y., Karch, C.M., Benitez, B.A., Jeng, A.T., Skorupa, T., Carrell, D., Bertelsen, S., Bailey, M., McKean, D., Shulman, J.M., De Jager, P.L., Chibnik, L., Bennett, D.A., Arnold, S.E., Harold, D., Sims, R., Gerrish, A., Williams, J., Van Deerlin, V.M., Lee, V.M., Shaw, L.M., Trojanowski, J.Q., Haines, J.L., Mayeux, R., Pericak-Vance, M.A., Farrer, L.A., Schellenberg, G.D., Peskind, E.R., Galasko, D., Fagan, A.M., Holtzman, D.M., Morris, J.C., Goate, A.M. 2013. GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimer's Disease. Neuron. doi:10.1016/j.neuron.2013.02.026.

Cruchaga, C., Kauwe, J.S., Mayo, K., Spiegel, N., Bertelsen, S., Nowotny, P., Shah, A.R., Abraham, R., Hollingworth, P., Harold, D., Owen, M.M., Williams, J., Lovestone, S., Peskind, E.R., Li, G., Leverenz, J.B., Galasko, D., Morris, J.C., Fagan, A.M., Holtzman, D.M., Goate, A.M. 2010. SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. PLoS Genet 6(9), pii: e1001101. doi:10.1371/journal.pgen.1001101.

Cruchaga, C., Kauwe, J.S., Nowotny, P., Bales, K., Pickering, E.H., Mayo, K., Bertelsen, S., Hinrichs, A., Fagan, A.M., Holtzman, D.M., Morris, J.C., Goate, A.M. 2012. Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease. Hum Mol Genet. doi:10.1093/hmg/dds296.

Cruchaga, C., Nowotny, P., Kauwe, J.S., Ridge, P.G., Mayo, K., Bertelsen, S., Hinrichs, A., Fagan, A.M., Holtzman, D.M., Morris, J.C., Goate, A.M. 2011. Association and Expression Analyses With Single-Nucleotide Polymorphisms in TOMM40 in Alzheimer Disease. Arch Neurol-Chicago 68(8), 1013-9. doi:10.1001/archneurol.2011.155.

Dreses-Werringloer, U., Lambert, J.C., Vingtdeux, V., Zhao, H., Vais, H., Siebert, A., Jain, A., Koppel, J., Rovelet-Lecrux, A., Hannequin, D., Pasquier, F., Galimberti, D., Scarpini, E., Mann, D., Lendon, C., Campion, D., Amouyel, P., Davies, P., Foskett, J.K., Campagne, F., Marambaud, P. 2008. A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk. Cell 133(7), 1149-61.

Fagan, A.M., Mintun, M.A., Mach, R.H., Lee, S.Y., Dence, C.S., Shah, A.R., LaRossa, G.N., Spinner, M.L., Klunk, W.E., Mathis, C.A., DeKosky, S.T., Morris, J.C., Holtzman, D.M.

2006. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59(3), 512-9.

Ford, J.W., McVicar, D.W. 2009. TREM and TREM-like receptors in inflammation and disease. Current opinion in immunology 21(1), 38-46. doi:10.1016/j.coi.2009.01.009.

Group, C.S. 2003. Vascular factors and risk of dementia: design of the Three-City Study and baseline characteristics of the study population. Neuroepidemiology 22(6), 316-25.

Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J.S., Younkin, S., Hazrati, L., Collinge, J., Pocock, J., Lashley, T., Williams, J., Lambert, J.C., Amouyel, P., Goate, A., Rademakers, R., Morgan, K., Powell, J., St George-Hyslop, P., Singleton, A., Hardy, J. 2013. TREM2 variants in Alzheimer's disease. N Engl J Med 368(2), 117-27. doi:10.1056/NEJMoa1211851.

Heath, S.C., Gut, I.G., Brennan, P., McKay, J.D., Bencko, V., Fabianova, E., Foretova, L., Georges, M., Janout, V., Kabesch, M., Krokan, H.E., Elvestad, M.B., Lissowska, J., Mates, D., Rudnai, P., Skorpen, F., Schreiber, S., Soria, J.M., Syvanen, A.C., Meneton, P., Hercberg, S., Galan, P., Szeszenia-Dabrowska, N., Zaridze, D., Genin, E., Cardon, L.R., Lathrop, M. 2008. Investigation of the fine structure of European populations with applications to disease association studies. Eur J Hum Genet 16(12), 1413-29. doi:10.1038/ejhg.2008.210.

Jonsson, T., Stefansson, H., Ph, D.S., Jonsdottir, I., Jonsson, P.V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A.I., Lah, J.J., Rujescu, D., Hampel, H., Giegling, I., Andreassen, O.A., Engedal, K., Ulstein, I., Djurovic, S., Ibrahim-Verbaas, C., Hofman, A., Ikram, M.A., van Duijn, C.M., Thorsteinsdottir, U., Kong, A., Stefansson, K. 2012. Variant of TREM2 Associated with the Risk of Alzheimer's Disease. N Engl J Med. doi:10.1056/NEJMoa1211103.

Kauwe, J.S., Cruchaga, C., Karch, C.M., Sadler, B., Lee, M., Mayo, K., Latu, W., Su'a, M., Fagan, A.M., Holtzman, D.M., Morris, J.C., Goate, A.M. 2011. Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer's disease. PLoS One 6(2), e15918. doi:10.1371/journal.pone.0015918.

Lambert, J.C., Ibrahim-Verbaas, C.A., Harold, D., Naj, A.C., Sims, R., Bellenguez, C., Jun, G., Destefano, A.L., Bis, J.C., Beecham, G.W., Grenier-Boley, B., Russo, G., Thornton-Wells, T.A., Jones, N., Smith, A.V., Chouraki, V., Thomas, C., Ikram, M.A., Zelenika, D., Vardarajan, B.N., Kamatani, Y., Lin, C.F., Gerrish, A., Schmidt, H., Kunkle, B., Dunstan, M.L., Ruiz, A., Bihoreau, M.T., Choi, S.H., Reitz, C., Pasquier, F., Hollingworth, P., Ramirez, A., Hanon, O., Fitzpatrick, A.L., Buxbaum, J.D., Campion, D., Crane, P.K., Baldwin, C., Becker, T., Gudnason, V., Cruchaga, C., Craig, D., Amin, N., Berr, C., Lopez, O.L., De Jager, P.L., Deramecourt, V., Johnston, J.A., Evans, D., Lovestone, S., Letenneur, L., Moron, F.J., Rubinsztein, D.C., Eiriksdottir, G., Sleegers, K., Goate, A.M., Fievet, N., Huentelman, M.J., Gill, M., Brown, K., Kamboh, M.I., Keller, L., Barberger-Gateau, P., McGuinness, B., Larson, E.B., Green, R., Myers, A.J., Dufouil, C., Todd, S., Wallon, D., Love, S., Rogaeva, E., Gallacher, J., St George-Hyslop, P., Clarimon, J., Lleo, A., Bayer, A., Tsuang, D.W., Yu, L., Tsolaki, M., Bossu, P., Spalletta, G., Proitsi, P., Collinge, J., Sorbi, S., Sanchez-Garcia, F., Fox, N.C., Hardy, J., Naranjo, M.C., Bosco, P., Clarke, R., Brayne, C., Galimberti, D., Mancuso, M., Matthews, F., Moebus, S., Mecocci, P., Del Zompo, M., Maier, W., Hampel, H., Pilotto, A., Bullido, M., Panza, F., Caffarra, P., Nacmias, B., Gilbert, J.R., Mayhaus, M., Lannfelt, L., Hakonarson, H., Pichler, S., Carrasquillo, M.M., Ingelsson, M., Beekly, D., Alvarez, V., Zou, F., Valladares, O., Younkin, S.G., Coto, E., Hamilton-Nelson, K.L., Gu, W., Razquin, C., Pastor, P., Mateo, I., Owen, M.J., Faber, K.M., Jonsson, P.V., Combarros, O., O'Donovan, M.C., Cantwell, L.B., Soininen, H., Blacker, D., Mead, S., Mosley, T.H., Jr., Bennett, D.A., Harris, T.B., Fratiglioni, L., Holmes, C., de Bruijn, R.F., Passmore, P.,

ACCEPTED MANUSCRIPT

Montine, T.J., Bettens, K., Rotter, J.I., Brice, A., Morgan, K., Foroud, T.M., Kukull, W.A., Hannequin, D., Powell, J.F., Nalls, M.A., Ritchie, K., Lunetta, K.L., Kauwe, J.S., Boerwinkle, E., Riemenschneider, M., Boada, M., Hiltunen, M., Martin, E.R., Schmidt, R., Rujescu, D., Wang, L.S., Dartigues, J.F., Mayeux, R., Tzourio, C., Hofman, A., Nothen, M.M., Graff, C., Psaty, B.M., Jones, L., Haines, J.L., Holmans, P.A., Lathrop, M., Pericak-Vance, M.A., Launer, L.J., Farrer, L.A., van Duijn, C.M., Van Broeckhoven, C., Moskvina, V., Seshadri, S., Williams, J., Schellenberg, G.D., Amouyel, P. 2013. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. doi:10.1038/ng.2802.

Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R. 2009. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25(16), 2078-9. doi:btp352 [pii] 10.1093/bioinformatics/btp352.

McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M. 1984. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34(7), 939-44.

Naj, A.C., Jun, G., Beecham, G.W., Wang, L.S., Vardarajan, B.N., Buros, J., Gallins, P.J., Buxbaum, J.D., Jarvik, G.P., Crane, P.K., Larson, E.B., Bird, T.D., Boeve, B.F., Graff-Radford, N.R., De Jager, P.L., Evans, D., Schneider, J.A., Carrasquillo, M.M., Ertekin-Taner, N., Younkin, S.G., Cruchaga, C., Kauwe, J.S., Nowotny, P., Kramer, P., Hardy, J., Huentelman, M.J., Myers, A.J., Barmada, M.M., Demirci, F.Y., Baldwin, C.T., Green, R.C., Rogaeva, E., George-Hyslop, P.S., Arnold, S.E., Barber, R., Beach, T., Bigio, E.H., Bowen, J.D., Boxer, A., Burke, J.R., Cairns, N.J., Carlson, C.S., Carney, R.M., Carroll, S.L., Chui, H.C., Clark, D.G., Corneveaux, J., Cotman, C.W., Cummings, J.L., Decarli, C., Dekosky, S.T., Diaz-Arrastia, R., Dick, M., Dickson, D.W., Ellis, W.G., Faber, K.M., Fallon, K.B., Farlow, M.R., Ferris, S., Frosch, M.P., Galasko, D.R., Ganguli, M., Gearing, M., Geschwind, D.H., Ghetti, B., Gilbert, J.R., Gilman, S., Giordani, B., Glass, J.D., Growdon, J.H., Hamilton, R.L., Harrell, L.E., Head, E., Honig, L.S., Hulette, C.M., Hyman, B.T., Jicha, G.A., Jin, L.W., Johnson, N., Karlawish, J., Karydas, A., Kaye, J.A., Kim, R., Koo, E.H., Kowall, N.W., Lah, J.J., Levey, A.I., Lieberman, A.P., Lopez, O.L., Mack, W.J., Marson, D.C., Martiniuk, F., Mash, D.C., Masliah, E., McCormick, W.C., McCurry, S.M., McDavid, A.N., McKee, A.C., Mesulam, M., Miller, B.L., Miller, C.A., Miller, J.W., Parisi, J.E., Perl, D.P., Peskind, E., Petersen, R.C., Poon, W.W., Quinn, J.F., Rajbhandary, R.A., Raskind, M., Reisberg, B., Ringman, J.M., Roberson, E.D., Rosenberg, R.N., Sano, M., Schneider, L.S., Seeley, W., Shelanski, M.L., Slifer, M.A., Smith, C.D., Sonnen, J.A., Spina, S., Stern, R.A., Tanzi, R.E., Trojanowski, J.Q., Troncoso, J.C., Van Deerlin, V.M., Vinters, H.V., Vonsattel, J.P., Weintraub, S., Welsh-Bohmer, K.A., Williamson, J., Woltjer, R.L., Cantwell, L.B., Dombroski, B.A., Beekly, D., Lunetta, K.L., Martin, E.R., Kamboh, M.I., Saykin, A.J., Reiman, E.M., Bennett, D.A., Morris, J.C., Montine, T.J., Goate, A.M., Blacker, D., Tsuang, D.W., Hakonarson, H., Kukull, W.A., Foroud, T.M., Haines, J.L., Mayeux, R., Pericak-Vance, M.A., Farrer, L.A., Schellenberg, G.D. 2011. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nature Genetics 43(5), 436-41. doi:10.1038/ng.801.

Patterson, N., Price, A.L., Reich, D. 2006. Population Structure and Eigenanalysis. PLoS Genet 2, e90.

Reitz, C., Mayeux, R. 2013. TREM2 and neurodegenerative disease. N Engl J Med 369(16), 1564-5. doi:10.1056/NEJMc1306509#SA1.

Woolf, B. 1955. On estimating the relation between blood group and disease. Ann Hum Genet 19(4), 251-3.

ACCEPTED MANUSCRIPT

TABLES AND FIGURES

Figure 1: Odds Ratios for rs9381040 (IGAP hit), rs3747742 (*TREML2*, p.S144G) and rs75932628 (*TREM2*, R47H) among AD patients, as compared with controls, at each study center and overall. Shown are the combined estimates of the AD risk of possessing rs9381040 (IGAP hit), combined odds ratios analyses were homogeneous (P = 0.69, by Woolf's test for heterogeneity). (Panel A), the rs3747742 (*TREML2*, p.S144G) (P = 0.81, by Woolf's test for heterogeneity) (Panel B), the rs75932628 (*TREM2*, p.R47H) (P = 0.97, by Woolf's test for heterogeneity) (Panel C), and rs75932628 (*TREM2*, p.R47H) after conditioning for rs3747742 (*TREML2*, p.S144G) (Panel D). The triangles represent ADGC study, the inverted triangles represent ARUK study, squares represent GERAD study, circles represent EADI study and the diamonds represent the summary odds ratio. The horizontal lines indicate the 95% confidence intervals of the estimates.

Figure 2: Association of *TREM2* and *TREML2* variants with CSF ptau levels. (Panel A). CSF ptau181 levels by rs9381040 genotype (IGAP meta-analysis most significant SNP). AG+GG vs AA p=0.04. (Panel B). CSF ptau181 levels by rs3747742 genotype (*TREML2*, missense variant p.S144G). AG+GG vs AA p=0.02. (Panel C). CSF ptau181 levels by rs75932628 genotype (*TREM2*, missense variant p.R47H)). AG vs AA p=0.0016. (Panel D). CSF ptau181 levels by rs3747742 genotype (*TREML2*, missense variant p.S144G). AG+GG vs AA excluding the variant p.R47H carriers p=0.03. The mean and the standard error of the mean (SEM) for the normalized residuals CSF ptau181 levels are shown in blue.

Figure 3: Microglial expression of *TREM2* and *TREML*2 show opposing effects in the presence of IL-1b. *TREM2* (Panel A) and *TREML2* (Panel B) gene expression were analyzed in primary mouse microglia and astrocytes activated by 0.2ng/mL IL-1β for 24 hrs. Induction of

Saa3 expression (Panel C) serves as a positive control for IL-1β stimulated activation.

ACCEPTED MANUSCRIPT

ACCEPTED MANUSCRIPT

Table 1: TREML2 variants identified by exome-sequencing

Location in chr6	rs#	AA change	EVS, MAF	AD (n=189)		Controls (n=225)		OR (95% CI)	p value	LD with rs9381040		Condel	Sift	Polyphen
				Hets	MAF	Hets	MAF			r2	D'			
41166154	rs77704965	D23G	0.22	0	0%	4	2%	--	0.17	0.018	1	Neutral	Tolerated	Benign
41166149	rs62396355	V25A	5.05	6	3%	15	7%	0.45 (0.17-1.2)	0.11	0.018	1	Neutral	Tolerated	Benign
41166075	rs35512890	M50V	--	16	8%	27	12%	0.67 (0.35-1.3)	0.24	--	--	Neutral	Tolerated	Benign
41162562	rs61734887	S129T	4.52	12	6%	22	10%	0.62 (0.30--1.3)	0.2	0.051	1	Neutral	Tolerated	Benign
41162538	--	L137H	--	0	0%	1	0%	--	0.35	--	--	Neutral	Tolerated	Benign
41162518	rs3747742	S144G	30.44	82	43%	104	47%	0.89 (0.6-1.31)	0.56	0.67	0.86	Neutral	Tolerated	Benign
41162371	rs145455750	T193A	0.27	0	0%	1	0%	--	0.35	--	--	Neutral	Tolerated	Benign
41162204	rs115991880	S248A	0.34	2	1%	5	2%	0.47 (0.09-2.45)	0.36	0	0	Deleterious	Deleterious	Benign

Coding variants in *TREML2* were extracted from 46 unrelated AD cases and 39 unrelated controls from the Knight-ADRC study and from 143 unrelated AD cases and 186 unrelated controls from the NIA-UK exome-sequencing study. The r^2 and D' values reported here are coming from the Pilot 1 of the 1000K genome project.

ACCEPTED MANUSCRIPT









ACCEPTED MANUSCRIPT

ACCEPTED MANUSCRIPT










A
Microglia TREM2
TREM2 relative expression
0.8
0.6
0.4
0.2
0.0
Control
IL-1b
B
Microglia TREML2
TREML2 relative expression
0.006
0.004
0.002
0.000
Control
IL-1b
C
Microglia Saa3
Saa3 relative expression
0.15
0.10
0.05
0.00
Control
IL-1b